10-Q: Scilex Reports Deepening Losses, Pivots to Crypto Amid Going Concern Doubt

Scilex Holding Company reported a significant increase in net losses and negative working capital, raising substantial doubt about its ability to continue as a going concern, while also adopting a new cryptocurrency treasury strategy.

Summary

• Net revenue for the nine months ended September 30, 2025, decreased by $16.2 million to $25.5 million, down from $41.7 million in the prior year, primarily due to a $15.6 million decrease in ZTlido sales.
• The company's net loss for the nine months ended September 30, 2025, surged to $327.9 million, a substantial increase from $66.3 million in the same period of 2024.
• Selling, general, and administrative expenses dramatically increased by $153.1 million to $236.7 million, largely driven by $140.0 million in issuance costs for the Semnur reverse recapitalization and $23.7 million in advisory and financing expenses.
• Research and development expenses rose by $5.1 million to $12.5 million, mainly due to additional expenses related to KDS2010 for Scilex Bio.
• A loss on derivative liability of $60.3 million was recognized for the nine months ended September 30, 2025, compared to a $2.4 million gain in the prior year, primarily due to changes in stock price and credit risk.
• The company reported a negative working capital of $342.5 million and cash and cash equivalents of only $0.9 million as of September 30, 2025.
• Management has concluded there is substantial doubt about the company's ability to continue as a going concern for at least one year from the financial statement issuance date.
• Scilex adopted a cryptocurrency treasury strategy in September 2025, beginning with the acquisition of $200.0 million in Bitcoin from the sale of Semnur Common Shares.
• The Semnur Business Combination was completed on September 22, 2025, with Denali changing its name to Semnur Pharmaceuticals, Inc. and its shares listing on OTC Markets.
• The company made an equity investment in Datavault AI Inc., acquiring 15 million shares for approximately $8.1 million, settled in Bitcoin, and subsequently sold 10.2 million Datavault shares for $20.7 million.
• A 1-for-35 reverse stock split was effected on April 15, 2025, to regain compliance with Nasdaq's minimum bid price requirement.
• The maturity date of the Oramed Note was extended to December 31, 2025, and amortization payments for the Tranche B Notes were deferred to October 8, 2026.

Sentiment

Score: 2

Explanation: The company faces severe financial distress, evidenced by massive losses, negative working capital, and explicit 'going concern' doubt. The new cryptocurrency treasury strategy is highly speculative, untested, and introduces significant additional risks, including regulatory uncertainty and extreme price volatility, which further compounds the existing operational and financial challenges in its core biopharmaceutical business. The substantial dilution risk from potential future capital raises and warrant exercises also weighs heavily on shareholder value.

Positives

• Operating cash flows increased to $21.3 million for the nine months ended September 30, 2025, up from $16.8 million in the prior year.
• The company recognized an unrealized gain of $8.3 million on its Datavault AI Inc. equity investment and a $4.7 million unrealized gain on digital assets (Bitcoin) for the nine months ended September 30, 2025.
• The second Phase 3 study for SP-102 (SEMDEXA) was initiated in September 2025, and SP-103 has an agreed path forward to a New Drug Application (NDA) with the FDA.
• ELYXYB received approval from Health Canada in January 2025 for the acute treatment of migraine in Canada, expanding its commercial reach.
• The company successfully regained compliance with Nasdaq's minimum bid price requirement following the reverse stock split.

Negatives

• Net revenue decreased by $16.2 million (38.9%) for the nine months ended September 30, 2025, compared to the same period in 2024, primarily due to reduced sales demand for ZTlido.
• Net loss significantly widened to $327.9 million for the nine months ended September 30, 2025, from $66.3 million in the prior year, indicating a substantial deterioration in profitability.
• Selling, general, and administrative expenses increased by $153.1 million, largely due to $140.0 million in issuance costs for the Semnur reverse recapitalization and $23.7 million in advisory and financing expenses.
• The company reported a negative working capital of $342.5 million and a low cash balance of $0.9 million as of September 30, 2025, highlighting severe liquidity challenges.
• An accumulated deficit of $888.7 million as of September 30, 2025, reflects sustained historical losses.
• The company recorded a $60.3 million loss on derivative liability for the nine months ended September 30, 2025, a significant reversal from a gain in the prior year.
• Losses from changes in fair value of debt and liability instruments increased to $36.5 million for the nine months ended September 30, 2025.

Risks

• The company has a limited operating history and has incurred significant losses since its inception, with anticipated continued losses for the foreseeable future.
• Substantial doubt exists about the company's ability to continue as a going concern due to recurring losses, negative cash flows, and a significant accumulated deficit.
• The terms of the Oramed Note and Tranche B Notes impose restrictive operating and financial covenants, and any failure to comply could result in an event of default, potentially leading to accelerated repayment or enforcement of security interests.
• The company will require substantial additional funding, which may not be available on acceptable terms or at all, potentially forcing a reduction in commercialization efforts or delays in product candidate development.
• Reliance on sole or single-source suppliers and manufacturers for commercial products and clinical supplies exposes the company to significant disruption risks, with some agreements allowing termination due to low net profits.
• The market price of the company's Common Stock may fluctuate significantly and investors may lose all or part of their investment, exacerbated by low trading liquidity and potential delisting from Nasdaq.
• The company's new cryptocurrency treasury strategy is untested and subject to inherent price volatility, regulatory uncertainty (potential classification as securities), and risks from the emergence of other digital assets.
• If deemed an investment company under the 1940 Act, applicable restrictions would likely make it impractical to continue segments of the business as currently contemplated.
• Regulatory developments related to crypto assets and markets, including enforcement actions, could adversely affect the business, financial condition, and results of operations.
• Changes in the accounting treatment of cryptocurrency holdings (ASU 2023-08) are expected to increase the volatility of financial results.
• Cryptocurrency holdings are less liquid than cash and cash equivalents and may not serve as a reliable source of liquidity, especially during market instability.
• Security breaches, cyberattacks, loss of private keys, or disruptions to cryptocurrency blockchains could result in the loss of some or all of the company's cryptocurrency holdings.
• Custodially-held cryptocurrencies may become part of a custodian's insolvency estate if the custodian enters bankruptcy, potentially leading to loss of value.
• The strategy of selling call options related to cryptocurrencies exposes the company to counterparty risk, where the counterparty may be unable or unwilling to honor its obligations.

Future Outlook

The company anticipates continued significant operating losses for the foreseeable future as it invests in commercialization efforts for ZTlido, GLOPERBA, and ELYXYB, and advances its product candidates (SEMDEXA, SP-103, SP-104) through clinical trials. It expects to finance operations through a combination of equity offerings, debt financings, collaborations, government contracts, or other strategic transactions, acknowledging that additional funding may not be available on favorable terms or at all. The company also plans to refine and formally adopt a cryptocurrency treasury strategy, including establishing an advisory board and engaging an asset manager, with a long-term strategy of holding Ethereum, bitcoin, BNB, Doge, and/or other blockchain-linked cryptocurrencies.

Management Comments

• We believe that our innovative non-opioid product portfolio has the potential to provide effective pain management therapies that can have a transformative impact on patients' lives.
• We target indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and are dedicated to advancing and improving patient outcomes.
• We intend to continue to explore and evaluate additional opportunities such as these to grow our business.
• Our management has concluded that there is substantial doubt about our ability to continue as a going concern for one year after the date the unaudited condensed consolidated financial statements are issued.
• We expect to continue to make investments in our sales and marketing organization and expand digital marketing efforts to broaden awareness of ZTlido, GLOPERBA and ELYXYB and in research and development, clinical trials and regulatory affairs to develop our product candidates, SEMDEXA, SP-103 and SP-104.
• Until we can generate significant revenue, if ever, we expect to finance our operations through a combination of equity offerings, debt financings, collaborations, government contracts or other strategic transactions.
• Our Board of Directors and senior management have been examining potential uses of cash, including acquisitions of cryptocurrency. After studying various alternatives, we decided that investing in cryptocurrency is currently a better use of our cash.
• We view cryptocurrency potentially as a core holding and expect to accumulate cryptocurrency following this offering.
• We intend to establish a cryptocurrency advisory board to assist in developing and managing our cryptocurrency treasury strategy.
• We intend to engage a third-party asset manager to execute the day-to-day management of our cryptocurrency holdings, in accordance with our treasury strategy and subject to the oversight of our cryptocurrency advisory board.

Industry Context

Scilex operates in the non-opioid pain management sector, a field with high unmet medical needs. The company's strategic pivot to a cryptocurrency treasury strategy is a significant departure from traditional biopharmaceutical operations, introducing exposure to the highly volatile and evolving digital asset market. This market is characterized by increasing regulatory scrutiny from bodies like the SEC and CFTC, as highlighted by the recent approval of spot bitcoin ETPs and ongoing legislative efforts like the CLARITY Act. The emergence of stablecoins and central bank digital currencies (CBDCs) further indicates a dynamic and competitive landscape within the broader digital asset industry, which could impact the value and regulatory treatment of Scilex's cryptocurrency holdings.

Comparison to Industry Standards

• The company's significant net losses and negative working capital are substantially below typical financial health benchmarks for established pharmaceutical companies.
• The adoption of a cryptocurrency treasury strategy is highly unconventional for a biopharmaceutical company, diverging significantly from standard treasury management practices in the industry.
• The explicit 'going concern' disclosure indicates a financial position weaker than most industry peers, suggesting a higher risk profile compared to global benchmarks for publicly traded pharmaceutical firms.

Corporate Governance

Legal Proceedings

• Former Employee Action: The court found in favor of the Plaintiffs (Scilex Pharma and Sorrento) against former President Anthony Mack, assessing costs against Mr. Mack for one-third of Plaintiffs' attorneys' fees. The parties are awaiting the entry of final judgment.
• ZTlido Patent Litigation: The U.S. District Court found that Aveva's generic product does not infringe Scilex's ZTlido Patents. The company is appealing this decision to the U.S. Court of Appeals for the Federal Circuit, with briefing completed and awaiting oral argument scheduling.
• Former Employees Litigation: A complaint filed by four former employees in California Superior Court for back compensation was settled on June 2, 2025, with confidential terms.

Related Party Transactions

• Sorrento Therapeutics, Inc. (former controlling stockholder): In September 2023, the company purchased 1,716,245 shares of Common Stock, 29,057,097 shares of Series A Preferred Stock, and various warrants from Sorrento. The Oramed Note replaced Sorrento's outstanding obligations to Oramed.
• Oramed Pharmaceuticals Inc.: Oramed is a significant creditor and investor, holding the Oramed Note and Tranche B Notes. The company also entered into the Gloperba-Elyxyb Royalty Purchase Agreement and an Option Agreement with Oramed to repurchase Penny Warrants. Oramed waived its right to participate in the Tranche B warrant exchange.
• SCLX JV (indirect wholly owned subsidiary): Delivered 142,855 shares of Common Stock to Tranche B Noteholders as consideration for deferring amortization payments.
• IPMC Company and NeuroBioGen Company (NBG): Scilex Bio (a controlled subsidiary) entered into a license agreement with IPMC and NBG for KDS2010, involving an upfront fee and potential milestone payments and royalties.
• Biconomy PTE Ltd: In September 2025, the company sold 12,500,000 Semnur Common Shares to Biconomy for $200.0 million in Bitcoin.
• Datavault AI Inc.: The company entered into a Securities Purchase Agreement to acquire Datavault Common Stock and a pre-funded warrant, settled in Bitcoin. Subsequently, a Datavault License Agreement was signed, and the company sold 10,224,112 Datavault shares, using $5.7 million to repurchase Bitcoin from Datavault.

Stakeholder Impact

• Shareholders: Face significant dilution risk from potential future equity offerings and warrant exercises. The market price of common stock is highly volatile, and there is a risk of delisting from Nasdaq. The reverse stock split may reduce trading liquidity. The new cryptocurrency strategy introduces substantial, untested risks.
• Employees: The sales force was transitioned to a third-party agency, impacting employment structure. Stock-based compensation plans are in place, but the value is tied to the company's volatile stock performance.
• Customers: Product availability could be impacted by supply chain disruptions due to reliance on sole or single-source suppliers.
• Creditors (Oramed, Tranche B Noteholders): Are exposed to the company's severe financial distress and 'going concern' doubt. Debt covenants provide some protection, but default remains a risk. The extension of debt maturities and deferral of payments indicate ongoing financial strain.
• Suppliers: Face risks related to the company's financial stability and ability to make payments, especially given the concentration risk with sole or single-source suppliers.

Next Steps

• Continue commercialization efforts for ZTlido, GLOPERBA, and ELYXYB.
• Advance development of product candidates SP-102 (SEMDEXA), SP-103, and SP-104, including initiating the second Phase 3 study for SP-102 and pursuing an NDA for SP-103.
• Seek substantial additional funding through equity offerings, debt financings, collaborations, government contracts, or other strategic transactions.
• Refine and formally adopt the cryptocurrency treasury strategy, including establishing a cryptocurrency advisory board and engaging a third-party asset manager.
• Datavault AI Inc. is required to file a preliminary proxy statement with the SEC within 25 days of September 26, 2025, and seek stockholder approval for the Datavault Pre-Funded Warrant terms and an increase in authorized shares.
• The first installment of the $10.0 million license fee to Datavault AI Inc. ($2.5 million) is due on or before December 31, 2025.
• The remaining $1.7 million payment to Tumim Stone Capital, LLC, as part of the termination agreement, is due on or before December 15, 2025.
• The Oramed Note's maturity date is extended to December 31, 2025, with a potential further extension to March 31, 2026, if the Penny Warrants repurchase is completed.
• The amortization payment for the Tranche B Notes is deferred until October 8, 2026.
• Awaiting the Federal Circuit's scheduling of oral argument for the ZTlido Patent Litigation appeal.
• Awaiting the entry of final judgment for the Former Employee Action against Mr. Mack.

Key Dates

Recommendation

Scilex Holding Company is in a precarious financial position, marked by a substantial increase in net losses, significant negative working capital, and an explicit 'going concern' disclosure. The core biopharmaceutical business is struggling with declining revenue, and while there's pipeline progress, it's insufficient to offset the immediate financial distress. The company's pivot to an untested cryptocurrency treasury strategy introduces an entirely new layer of high-risk, speculative exposure to a volatile and uncertain regulatory environment, further complicating its financial outlook. The potential for significant shareholder dilution from future capital raises, coupled with the inherent risks of both its traditional and new business segments, makes this a highly speculative and risky investment. A seasoned investor would likely view the current financial state and strategic shift as a strong indicator to exit the position.

Keywords

Non-opioid pain management, Biopharmaceutical, SEC filing, 10-Q, Scilex Holding Company, SCLX, ZTlido, GLOPERBA, ELYXYB, SEMDEXA, SP-102, SP-103, SP-104, Clinical trials, FDA approval, Cryptocurrency, Bitcoin, Digital assets, Treasury strategy, Going concern, Net loss, Revenue decline, Liquidity, Debt covenants, Reverse stock split, Nasdaq compliance, Datavault AI, Semnur Business Combination, Derivative liability, Financial reporting, Risk factors